BB's Stock Haven

[jaybird249]

DD Summary SNSS $.88 + $.11 32 Million volume
1) ANALYST COMMENTS:
Hedge Fund $3 - $5 Target (March 26 2010)
http://www.themarketguardian.com/2010/03/radar-play-snss/

Jefferies $2 Target (Feb 12 2010)
Jefferies & Co raises their SNSS tgt to $2 from $1.50 saying they believe SNSS may have made progress in FDA negotiations over its Voreloxin registration strategy and design of pivotal AML trial. Firm says this should incrementally decrease regulatory risk and bring SNSS closer to a potential Voreloxin partnership or becoming an acquisition candidate.

2) MAJOR DRUG COMPANY INVESTMENT:
Bristol-Myers Squibb Company bought 3.7% in SNSS (February 2010)
http://ir.sunesis.com/sec.cfm

3) BUYOUT / PARTNERSHIPS
Sunesis Pharmaceuticals' Chief Financial Officer Eric Bjerkholt told Reuters that the company was already in talks for a partnership on Dec. 11, 2009. Now, 3 months passed and it's about time for the deal to close.

4) DRUG RESULTS. The following results are SPECTACULAR. Median survival INCREASED 7.8 months (DNDN's drug increases survival by 2 months)

a) Voreloxin demonstrated strong dose-dependent tumor growth inhibition (63-88%) in 10 of 11 solid tumor (breast, ovarian, colon, lung, gastric, and melanoma) xenograft models, 2 hematologic tumor xenograft models, 3 multidrug resistant tumor models and 3 murine syngeneic tumor models (Colon 26, Lewis Lung carcinoma, M5076 Ovarian Sarcoma). CONCLUSIONS: These data demonstrate that voreloxin is a broadly active anti-tumor agent in vitro and in vivo, with potent activity in aggressive and drug-resistant tumor models. Tens of billions of market opportunity!

b) Voreloxin works on patients that failed on Avastin in ovarian cancer.

c) 31% REMISSION RATE and Phase 3 Trial of Voreloxin in Acute Myeloid Leukemia (Voreloxin, unique anti-leukemic activity and tolerability).

d) The phase 1b/2 is even better; in which, the median survival rate is 7.8 months, and the 30 day and 60 day mortality rates are merely 1% and 8%. Yet no drug in the world has acheived such great results for this disease. The FDA will likely fast-track it.